Wegovy Cost in Indiana (2026): Prices, Insurance, and Savings Options

Wegovy contains semaglutide 2.4 mg, a GLP-1 receptor agonist administered via once-weekly subcutaneous injection for chronic weight management. Although Wegovy and Ozempic both contain semaglutide, Ozempic uses lower doses (0.5-2 mg) and carries FDA approval for type 2 diabetes rather than weight loss. Because of these distinct dosages and indications, insurers and Medicaid programs frequently apply different coverage policies to each medication, sometimes resulting in different treatment of the two drugs for a single individual.

This is a pending-review draft. It has not yet completed qualified medical and pricing review. Every dollar figure below is a snapshot that can change without notice; verify current numbers before making a purchasing or coverage decision.

The direct answer

Novo Nordisk's publicly reported list price for Wegovy has been in the range of roughly $1,300-$1,350 per month for a four-pen supply, and Indiana cash-pay pharmacy prices generally track that list price rather than deviating meaningfully by region. What actually determines a given Hoosier's out-of-pocket cost is not the list price but which of four levers applies to them: commercial insurance with a covered formulary, the manufacturer savings card, a compounded alternative from a licensed pharmacy, or a patient assistance program. Indiana Medicaid, as a matter of program design rather than local pricing, does not cover Wegovy for weight management, only semaglutide at diabetes doses under separate criteria. None of these facts should be treated as fixed; insurer formularies, cash prices, and shortage-driven compounding availability all change during the year and need to be reconfirmed at the time of prescribing.

What is established versus what needs verification

Established by FDA action and labeling:

• Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, and separately for reducing the risk of major cardiovascular events in adults with cardiovascular disease and obesity or overweight. See the FDA press announcement on the cardiovascular risk-reduction approval and the Wegovy prescribing information.
• Compounded semaglutide is legal only when a licensed pharmacy prepares it under a patient-specific prescription, consistent with federal pharmacy compounding law governing 503A pharmacies. Compounding is not FDA-approved manufacturing, and compounded semaglutide has not undergone the same premarket review as branded Wegovy.
• Semaglutide has appeared on the FDA drug shortage list at points in the recent past, which affects whether larger 503B outsourcing facilities can legally compound it. Shortage status changes and must be checked at the time of prescribing, not assumed from an earlier snapshot.

Plausible but not verified in this draft, and needing confirmation before you rely on it:

• The exact current Indiana cash-pay price at a specific pharmacy chain.
• Whether a specific commercial insurer (for example, a named Anthem, UnitedHealthcare, or CareSource product) covers Wegovy this plan year. Coverage is set at the individual plan and employer level, not statewide, and changes at renewal.
• The current price of compounded semaglutide 2.4 mg from any specific Indiana 503A pharmacy.
• Whether Medicare Part D plans in Indiana currently cover Wegovy, and under what prior authorization terms, given that Medicare anti-obesity drug coverage policy has been in flux.

Not established:

• That Indiana Medicaid coverage policy will change in the near term. As of this draft there is no confirmed statewide mandate for anti-obesity medication coverage under Indiana Medicaid or the Healthy Indiana Plan.

Indiana Medicaid and Wegovy

Indiana Medicaid's general posture, consistent with many state Medicaid programs, has been to cover semaglutide only under its diabetes-indicated brand and dosing (Ozempic, 0.5-2 mg) when type 2 diabetes is the documented treatment goal, and not to cover Wegovy (2.4 mg) for weight management alone. This is a program design choice, not a pricing artifact, and it is consistent across traditional Medicaid and the Healthy Indiana Plan. Confirm current formulary status directly with Indiana Medicaid or your managed care entity before assuming either outcome, since state formularies are revised periodically and coverage advocacy in this space is active nationally.

Professional bodies including the Endocrine Society and the American Association of Clinical Endocrinology have published guideline-level positions favoring broader insurance access to FDA-approved anti-obesity medications for patients who meet clinical criteria. These are guideline recommendations, not binding coverage rules, and Indiana's Medicaid formulary has not adopted them for Wegovy as of this draft.

Commercial insurance: what varies and what to ask

Commercial coverage for Wegovy is inconsistent across employers, plan tiers, and pharmacy benefit managers, and national data on GLP-1 obesity-drug coverage has shown substantial gaps in employer plans, though the exact current percentage of plans covering a GLP-1 for obesity is a moving target and should not be quoted as a fixed statistic without checking a current source. When a plan does cover Wegovy, prior authorization is common, typically requiring documented BMI in the approved range, a weight-related comorbidity if BMI is 27-29.9, and evidence of a prior lifestyle intervention attempt. Some plans layer on step therapy requiring an older, cheaper agent first.

The single most useful thing a patient can do is call the number on the insurance card and ask specifically about "semaglutide 2.4 mg, brand Wegovy," because coverage for semaglutide at diabetes doses does not imply coverage at the weight-management dose. Specialty-tier placement (often Tier 4 or 5) tends to produce higher copays even when a drug is nominally covered.

The manufacturer savings card and patient assistance

Novo Nordisk provides a manufacturer savings card designed to lower out-of-pocket expenses for commercially insured individuals who have existing Wegovy benefits, along with a separate patient assistance program for uninsured individuals meeting income requirements. Historically, both initiatives have not been available to patients enrolled in Medicare, Medicaid, TRICARE, or comparable government programs. Manufacturer savings-card maximums, fill limits, and PAP eligibility thresholds are revised regularly and require verification through Novo Nordisk's official patient resources rather than relying on previous year information. The savings card functions to reduce an existing copayment only and cannot establish coverage for plans that do not include Wegovy.

Compounded semaglutide: legal pathway, real tradeoffs

Compounded semaglutide 2.4 mg is available through licensed 503A pharmacies at a price that has generally been reported as substantially below brand Wegovy's list price, though the specific dollar figure varies by pharmacy and should be confirmed at the time of prescribing rather than treated as fixed. Legality depends on the pharmacy holding an active state pharmacy board license, compounding from an appropriate active pharmaceutical ingredient source, and dispensing against a valid patient-specific prescription under the federal 503A framework.

Compounded product is not FDA-approved and quality assurance is the patient's and prescriber's responsibility rather than guaranteed by federal premarket review. Before using a compounded product, verify the pharmacy's state board license, ask whether it is accredited by a pharmacy compounding accreditation body, and request a certificate of analysis for potency and sterility. Compounded semaglutide is typically dispensed in a multi-dose vial rather than a pre-filled pen, which means dosing accuracy depends on correct syringe technique; patients switching from a pen should get explicit injection training rather than improvise.

Telehealth prescribing in Indiana

Indiana permits telehealth prescribing of Wegovy without a mandatory in-person visit, provided the prescriber conducts a real clinical evaluation, typically synchronous audio-video, and holds an active Indiana license or practices under a valid interstate licensure arrangement. Because semaglutide is not a controlled substance, controlled-substance telehealth restrictions do not apply to it. Telehealth can shorten access delays compared with waiting for a specialist appointment, and platforms that partner with compounding pharmacies can ship medication directly, but pricing structures (membership fee plus medication versus bundled pricing) differ by platform and should be compared explicitly before enrolling.

What the trial evidence actually shows, and its boundary

Wegovy's weight-management approval rests on a randomized trial program (the STEP trials) summarized in its FDA label, in which semaglutide 2.4 mg produced meaningfully greater mean body weight loss than placebo over roughly 68 weeks in adults with obesity or overweight with a comorbidity; the label is the authoritative source for the exact percentages and should be checked directly rather than relied on from secondary retellings. Separately, a large randomized cardiovascular outcomes trial supported a 2024 FDA label expansion for reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, as described in FDA's own announcement. Both are trial-level evidence in defined populations; neither trial establishes that these effect sizes generalize to patients well outside the enrolled BMI range, age range, or cardiovascular risk profile, and neither addresses long-term outcomes beyond the trial follow-up windows.

Gastrointestinal adverse effects (nausea, diarrhea, vomiting, constipation) are common, occur more often during dose escalation, and lead a meaningful minority of patients to discontinue treatment; exact discontinuation rates are in the FDA label and should be read there rather than restated as a rounded figure here.

Cheapest realistic paths, by starting situation

• Commercially insured with Wegovy on formulary: confirm the copay tier, then ask whether a manufacturer savings card can apply on top of it.
• Commercially insured but Wegovy excluded or denied: ask the prescriber about a letter of medical necessity and formal appeal before assuming compounding is the only option; appeals sometimes succeed, especially with documented comorbidities.
• Uninsured: check current patient assistance program income eligibility before assuming it does not apply, since thresholds are periodically updated; if ineligible, compare compounded pricing from a verified 503A pharmacy against brand cash price.
• Indiana Medicaid enrollee without a diabetes indication: there is currently no confirmed covered pathway to Wegovy specifically for weight management; compounded semaglutide through a licensed pharmacy is an out-of-pocket alternative, not a covered benefit.

Discount cards such as GoodRx sometimes list Wegovy at a modest discount off cash price, but these generally cannot be combined with insurance or the manufacturer savings card, and the discount size fluctuates.

Verification checklist: stable facts versus facts that expire

Use this before quoting a price or coverage rule to anyone, including yourself.

Stable (federal, regulatory, or clinical; unlikely to change month to month)

• Wegovy's FDA-approved indications (weight management; cardiovascular risk reduction in the labeled population), confirm against the current FDA label, not a summary.
• That semaglutide 2.4 mg (Wegovy) and semaglutide at diabetes doses (Ozempic) are different labeled products even though the active ingredient is the same.
• That compounding is only legal under a patient-specific prescription from a licensed 503A (or eligible 503B) pharmacy, and that compounded product is not FDA-approved.
• The general adverse-effect profile (GI symptoms common, more frequent during dose escalation).

Volatile (must be re-checked at the date you act, not assumed from this article)

• Current Wegovy list price and Indiana pharmacy cash price.
• Current FDA drug shortage status for semaglutide, which affects 503B compounding legality.
• Whether your specific commercial plan (not "insurers in Indiana" generally) covers Wegovy this plan year, and its prior authorization criteria.
• Whether Indiana Medicaid or HIP has changed its anti-obesity medication coverage policy since this draft's date.
• Current manufacturer savings card terms and patient assistance program income thresholds.
• The specific compounding pharmacy's current price, license status, and whether it provides a certificate of analysis.
• Current Medicare Part D coverage status and prior authorization rules, if applicable.

If a number in this article does not match what your pharmacy, insurer, or Medicaid caseworker tells you today, trust the person you spoke to today. Prices and coverage rules in this space move faster than most published pages, including this one.

When to seek urgent or in-person care

Cost-related delays or gaps in access are not a reason to substitute an unverified or unlicensed compounded product, or to skip clinical follow-up. Seek prompt medical attention for symptoms such as severe abdominal pain (possible pancreatitis), signs of gallbladder disease, persistent vomiting with dehydration, or any allergic reaction after injection. This article does not provide individualized dosing guidance; dosing decisions, including dose escalation and management of side effects, should be made with a prescribing clinician.